Author(s)

Zhuguang Liu ¹, Junxiu Zou ¹

Affiliation(s)

¹ School of Economics, Guangxi University, Nanning, China

Corresponding Author

Zhuguang Liu

ABSTRACT

Although China's pharmaceutical industry industry has shown a leading momentum in some fields, it is still in the relatively low-end position of the global value chain, which is mainly restricted by the shortcomings of research and development capacity, the limitation of policy environment, the slow industrialization process and the gradual weakening of cost advantage. From the perspective of global value chain, this paper discusses the current development trend and internal characteristics of pharmaceutical manufacturing industry, as well as the possible path and strategy to improve its status. Based on this, this paper puts forward the path and strategy of upgrading the global value chain of pharmaceutical manufacturing industry, so as to improve its position and competitiveness in the global value chain.

KEYWORDS

Pharmaceutical Industry; Global Value Chains; Tchnological Innovation; Industrial Upgrading

CITE THIS PAPER

Zhuguang Liu, Junxiu Zou, Pathways and Strategies for Enhancing the Global Value Chain Position of China's Pharmaceutical Industry. Industrial Engineering and Innovation Management (2024) Vol. 7: 1-9. DOI: http://dx.doi.org/10.23977/ieim.2024.070301.

REFERENCES

[1] Chen, K., Ying, X. W., Wu, Y. Q., & Lin, Z. J. (2018). Research on the Development Status of Domestic Medical Manufacturing Industry Based on Patent Analysis and Bibliometrics. Science and Technology Management Research, 38(2), 103-111.
[2] Pu, R., Guan, Z. H., Su, Y., Geng, X. N., & Ao, Y. (2014). A Brief Discussion on the Current Status of Research and Development in China's Pharmaceutical Industry and Suggestions for Future Development. China Biotechnology, 34(7), 114-119.
[3] Zhou, B., & Wu, X. M. (2014). Development Trend and Prospect Analysis of Biopharmaceutical Manufacturing Industry. Chinese Journal of Pharmaceuticals, 45(7), 703-705.
[4] Zhang, T., Lu, Y., Chen, J., & Ouyang, Z. L. (2020). The Technological Innovation in the Biomedicine Field in China. Chinese Journal of New Drugs, 29(22), 2521-2527.
[5] Wu, L., & Chen, Y. F. (2017). Novel drug research and development ability in China: An international comparison and analysis. Chinese Journal of Health Policy, 10(8), 23-28.
[6] Yang, S. J., & Wu, Z. A.  (2020). Analysis on Innovation Input-output in China’s Pharmaceutical Enterprises from the Perspective of Patent Application. China Pharmacy, 31(2), 129-132.
[7] Xu, F. J., & Zhang, Y. T. (2020). Innovation in the scientific research management system of China's biomedical industry. Continuing Medical Education, 34(12), 69-71.
[8] Shi, G., & Liu, F. Y. (2016). The status quo and strategies on biotechnological medicine industry development in China. Chinese Journal of Health Policy, 9(3), 16-19.
[9] Duan, X. T., Lian, G. Y., & Jia, Y. Z. (2017). Barriers and Measures of Innovative Drug Entering Health Insurance Directory in China. China Pharmacy, 28(4), 455-457.
[10] Wang, H. Y., Cong, L. X., Xie, C. Y., Wang, M. F., Liu, X., & Jin, C. L. (2021). Progress and Consideration on the Medical Insurance Payment Reform for Innovative Drugs in China. Health Economics Research. 38(01), 47-49
[11] Zhang, Z. X., Wu, J. H., Yi, Y., Hao, L. M., Xie, J. X., & Qi, J. C. (2019). Overview of the development of key protection technologies and equipment for biosafety laboratories in China. Chinese Journal of Public Health Engineering, 18(5), 641-646.
[12] Casadevall, A. (2021). The mRNA vaccine revolution is the dividend from decades of basic science research. The Journal of Clinical Investigation, 131(19).
[13] Li, T. Z., Ma, J., Liang, M. M., & Feng, W. (2013). Analysis on Transition of Technology Trajectory and Opportunity in Bio-pharmaceutical Industry. Technology Economics, 32(7), 4-12.
[14] Wang, X. G. (2022). Accelerating the Innovation and Upgrading of Biomedical Industry to Promote High-quality Development of Bioeconomy. China Biotechnology, 42(5), 8-9.
[15] Gottinger, H. W., & Umali, C. L. (2008). The evolution of the pharmaceutical-biotechnology industry. Business History, 50(5), 583-601.
[16] Wang, L., & Kang, C. H. (2005). Research on R&D Strategic Alliance of Pharmaceutical Enterprises in China. Science and Technology Management Research, 25(12), 111-113.
[17] Quintana-García*, C., & Benavides-Velasco, C. A. (2005). Agglomeration economies and vertical alliances: the route to product innovation in biotechnology firms. International Journal of Production Research, 43(22), 4853-4873.
[18] Yang, D. H. (2009). The Deepening Disassembly of Value Chain, Outsourcing Network and Core Competency - a Study of Pharmaceutical Industry. Business and Management Journal, 31(12), 23-31.
[19] DeCorte, B. L. (2020). Evolving Outsourcing Landscape in Pharma R&D: Different Collaborative Models and Factors To Consider When Choosing a Contract Research Organization: Miniperspective. Journal of Medicinal Chemistry, 63(20), 11362-11367.
[20] Li, G. P., & Fang, X. H. (2016). Spatial Layout Pattern of International Biopharmaceutical Company in China Based on Value Chain Specialization. Areal Research and Development, 35(4), 6-11.
[21] Zhang, Y., Wang, S., & Chen, Y. W. (2020). Research on Relationship Between Foreign Companies 'R&D Investment in China and Local Enterprises' R&D investment: Based on China's Pharmaceutical Manufacturing Industry. Science and Technology Management Research, 40(23), 108-114.
[22] Cao, P., Wang, Y., & Zhu, C. H. (2009). Discussing The Independent Innovation of China’S Pharmaceutical Indus- Try From Investment, Personnel And Policies. Modern Preventive Medicine, 36(2), 263-264.
[23] Li, J., Jiang, K. J., & Wang, Y. H. (2017). Analyzing the Upgrading Mode of Bio-Pharmaceutical Industry Cluster In View Of Industry Value Chain. Chinese Health Service Management, 34(12), 884-887+894.
[24] Tang, X. J., & Li, X. Y. (2012). Fiscal and Tax Incentives Analysis for Enhancing Independent Innovation Capability in Pharmaceutical Manufacturing Industry. Commercial Research, (2), 77-81.
[25] Wang, X. G., & Yang, J. R. (2019). Development Directions for the Transformation and Upgrading of Chinese Pharmaceutical Industry. Chinese Journal of Pharmaceuticals, 50(06), 681-686.

Sponsors, Associates, and Links

---

• Information Systems and Economics
  
  
• Accounting, Auditing and Finance
  
  
• Tourism Management and Technology Economy
  
  
• Journal of Computational and Financial Econometrics
  
  
• Financial Engineering and Risk Management
  
  
• Accounting and Corporate Management
  
  
• Social Security and Administration Management
  
  
• Population, Resources & Environmental Economics
  
  
• Statistics & Quantitative Economics
  
  
• Agricultural & Forestry Economics and Management
  
  
• Social Medicine and Health Management
  
  
• Land Resource Management
  
  
• Information, Library and Archival Science
  
  
• Journal of Human Resource Development
  
  
• Manufacturing and Service Operations Management
  
  
• Operational Research and Cybernetics